drugset / Trial / NCT02865629

N-acetylcysteine in the Treatment of Depressive Symptoms in Bipolar Offspring

NCT02865629

Unknown 22 enrolled University of Cincinnati
NaSingle-groupOpen-labelTreatment

Summary

N-acetylcysteine in the treatment of depressive symptoms in youth at high-risk for bipolar disorder: a functional connectivity study

Timeline

Start
2016-08
Primary completion
2019-08
Completion
2019-09

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 1200 mg Oral

Indications